Immuron Ltd
IMRN · XNASCIK 1660046fmd_1W9W8KT926E6JA40VG6A72ZN15Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2015 to Jun 30, 2026, 13 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 1 | 1 | 2 | 3 | 0 | 1 | 2 | 5 | 7 |
| Cost of revenue | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 2 | 3 |
| Gross profit | 1 | 1 | 1 | 2 | 2 | 0 | 1 | 1 | 3 | 5 |
| Research and development | 4 | 5 | 2 | 1 | 1 | 1 | 1 | 3 | 5 | 4 |
| Selling, general and administrative | 0 | 0 | 0 | – | – | – | – | – | – | – |
| Operating income | – | (7) | (3) | (5) | (3) | (8) | (3) | (4) | (6) | (5) |
| Interest expense | 0 | 0 | 0 | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before taxes | (7) | (7) | (3) | (5) | (3) | (8) | (3) | (4) | (7) | (5) |
| Net income | (7) | (7) | (3) | (5) | (3) | (8) | (3) | (4) | (7) | (5) |